AACR 2020: MET Inhibitor Therapy in Lung Cancer With Brain Metastasis
Posted: Thursday, May 7, 2020
The highly selective MET inhibitor capmatinib appears to cross the blood-brain barrier, providing durable antitumor activity in patients with non–small cell lung cancer (NSCLC) who have brain metastasis. Capmatinib was also active in patients with MET exon 14–mutated NSCLC. Edward B. Garon, MD, of the University of California, Los Angeles, and colleagues presented the findings of the GEOMETRY mono-1 study as a part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract CT082).
This phase II, multicenter study recruited 97 patients with stage IIIB/IV NSCLC, including those with neurologically stable or asymptomatic brain metastasis. The patients were administered 400 mg of capmatinib twice a day. Patients were assigned to be in cohort 4, where they had previously received treatments, or cohort 5b, where patients were treatment-naive.
The overall response rate was 40.6% for patients in cohort 4 and 67.9% for patients in cohort 5b. The median duration of response was 9.72 and 11.14 months for cohorts 4 and 5b, respectively, and the median progression free survival was 5.42 and 9.69 months, respectively.
There were 13 patients with baseline brain metastasis by the blinded independent central review committee, and 7 of them had an intracranial response to capmatinib. In addition, four patients saw complete resolution of their brain lesions, whereas other patients’ brain lesions underwent various combinations of stabilization, reduction in size, and resolution. Intracranial disease control was achieved in 12 of the 13 patients.
The most common treatment-related adverse events of any grade across all cohorts (N = 334) included peripheral edema (41.6%), nausea (33.2%), increased blood creatinine level (19.5%), and vomiting (18.9%).
Disclosure: For a full list of author disclosures, visit abstractsonline.com.
